1. Clinical & Scientific Overview
Senna Leaf & Pod (Senna alexandrina) (TIP-MED-000603, Reference Code [BOT-24]) is classified under
Medicinal Plants, Botanicals & Phytopharmaceuticals as a Pharmacognosy & Phytochemistry • Fabaceae (Dried Leaflets and Dried Ripe Pods).
Within the Indian regulatory and compendial framework, it is governed under Indian Pharmacopoeia (IP) Official Monograph and API Part I Vol I..
Standardised Pharmacopoeial Crude Drug / Extract (IP / API Reference)
Official Plant Part: Dried Leaflets and Dried Ripe Pods | Marker Compounds: Dianthrone glycosides — Sennosides A, B, C, and D (calculated as Sennoside B: IP requires >=2.0% w/w in leaf and >=2.5% w/w in pod)
Pharmacognosy, Phytochemistry & Botanical Standardisation
Accepted Botanical Binomial & Authority: Senna alexandrina Mill. (syn. Cassia angustifolia Vahl — Tinnevelly Senna)
Botanical Family: Fabaceae
Official Authenticated Plant Part: Dried Leaflets and Dried Ripe Pods
Major Phytochemical Constituents & IP/API Marker Compounds: Dianthrone glycosides — Sennosides A, B, C, and D (calculated as Sennoside B: IP requires >=2.0% w/w in leaf and >=2.5% w/w in pod)
Traditional / Classical Ayurvedic Context: India (Tirunelveli, Tamil Nadu) is the world's primary cultivator of pharmacopoeial Tinnevelly Senna, used as an acute stimulant purgative.
Modern Clinical Evidence Assessment (Clearly Distinguished from Traditional Use): Colonic bacteria hydrolyse sennosides into rhein-anthrone, which stimulates myenteric plexus Auerbach neurons and inhibits colonic Na+/K+-ATPase water absorption, producing bowel evacuation in 6–12 hours.
Quality Control, Adulteration & Contaminant Limits: Authenticate via HPTLC/HPLC marker assay; screen for heavy metals (Lead <=10 ppm, Arsenic <=3 ppm, Cadmium <=0.3 ppm, Mercury <=1 ppm), microbial load, and aflatoxins B1/B2/G1/G2 per IP/API.
Indian Regulatory Classification (ASU vs Phytopharmaceutical vs FSSAI): Indian Pharmacopoeia (IP) Official Monograph and API Part I Vol I.
3. Mechanism of Action & Pharmacodynamics
Major Phytochemical Constituents & Pharmacological Actions: Dianthrone glycosides — Sennosides A, B, C, and D (calculated as Sennoside B: IP requires >=2.0% w/w in leaf and >=2.5% w/w in pod). Colonic bacteria hydrolyse sennosides into rhein-anthrone, which stimulates myenteric plexus Auerbach neurons and inhibits colonic Na+/K+-ATPase water absorption, producing bowel evacuation in 6–12 hours.
4. Therapeutic Indications & Evidence-Supported Uses
- Traditional / Classical Context: India (Tirunelveli, Tamil Nadu) is the world's primary cultivator of pharmacopoeial Tinnevelly Senna, used as an acute stimulant purgative.
- Modern Clinical Evidence Assessment: Colonic bacteria hydrolyse sennosides into rhein-anthrone, which stimulates myenteric plexus Auerbach neurons and inhibits colonic Na+/K+-ATPase water absorption, producing bowel evacuation in 6–12 hours.
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Pharmacognostic & Clinical Evidence Summary: Colonic bacteria hydrolyse sennosides into rhein-anthrone, which stimulates myenteric plexus Auerbach neurons and inhibits colonic Na+/K+-ATPase water absorption, producing bowel evacuation in 6–12 hours.
Administration & Meal Timing: Authenticated Plant Part Used: Dried Leaflets and Dried Ripe Pods. RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Complex multicomponent phytoconstituent disposition involving intestinal deglycosylation by gut microbiota, hepatic Phase II glucuronidation/sulfation, and potential modulation of CYP450 and P-gp efflux pumps.
Intestinal microbial hydrolysis and hepatic Phase I/II biotransformation of secondary metabolites.
Avoid unstandardised herbal extracts in Stage 3–5 Chronic Kidney Disease (risk of hyperkalaemia or nephrotoxic adulterants).
Avoid high-dose concentrated botanical extracts in pre-existing hepatic disease; discontinue immediately if jaundice or transaminase elevation occurs.
7. Contraindications, Precautions & High-Risk Warnings
- Hypersensitivity to Senna alexandrina Mill. (syn. Cassia angustifolia Vahl — Tinnevelly Senna) or other members of the Fabaceae family
- RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
Key Clinical Precautions: RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
8. Adverse Effects Profile
- RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
- RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Verify botanical binomial authenticity (exclude adulterants/substitutes), HPTLC marker content, heavy metal limits (Pb, As, Cd, Hg), aflatoxins, and pesticide residues per IP/API standards.
Pharmacist Patient Counselling Points:
- Natural or herbal origin does NOT automatically mean risk-free; always disclose botanical supplements to your doctor and pharmacist.
- RESTRICT TO SHORT-TERM USE (<=1–2 weeks): Chronic stimulant laxative abuse causes hypokalaemia (potentiating digoxin toxicity and arrhythmias), cathartic colon, abdominal cramps, and benign reversible brown-black colonic mucosal pigmentation (Melanosis coli); contraindicated in intestinal obstruction, appendicitis, and inflammatory bowel disease.
- Never discontinue prescribed allopathic chronic disease medicines (antihypertensives, antidiabetics, anticonvulsants, or antivirals) in favour of unverified herbal products.
Storage, Stability & Dispensing Safeguards: Store dried botanical material and extracts in airtight, light-resistant containers below 25°C protected from humidity and fungal/aflatoxin contamination.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP — Herbs and Herbal Products Addendum); Ayurvedic Pharmacopoeia of India (API — Ministry of AYUSH); CDSCO Rule 122E Phytopharmaceutical Drug Guidelines.
Official Verification Portals: Ministry of AYUSH — Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) • Indian Pharmacopoeia Commission (IPC) — Herbal Monographs • CDSCO — Drugs and Cosmetics Rules (ASU & Phytopharmaceuticals)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [BOT-04] Giloy / Guduchi (Tinospora cordifolia) — Pharmacognosy & Phytochemistry • Menispermaceae (Dried Mature Ste
- [BOT-05] Brahmi (Bacopa monnieri) — Pharmacognosy & Phytochemistry • Plantaginaceae (formerly Scrophu
- [BOT-06] Mandukaparni / Gotu Kola (Centella asiatica) — Pharmacognosy & Phytochemistry • Apiaceae (Dried Whole Aerial Pla
- [BOT-07] Amla / Indian Gooseberry (Phyllanthus emblica) — Pharmacognosy & Phytochemistry • Phyllanthaceae (Fresh or Dried P
